Systems Pharmacology Dissecting Holistic Medicine for Treatment of Complex Diseases: An Example Using Cardiocerebrovascular Diseases Treated by TCM

Evidence-based Complementary and Alternative Medicine

Volumn 2015, Issue , 2015, Pages

  Wang, Yonghua ^a   Zheng, Chunli ^b   Huang, Chao ^b   Li, Yan ^c   Chen, Xuetong ^b   Wu, Ziyin ^b   Wang, Zhenzhong ^d   Xiao, Wei ^d   Zhang, Boli ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b NORTHWEST A F UNIVERSITY   (China)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

^d State Key Laboratory of New Tech for Chinese Medicine Pharmaceutical Process   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 ALPHA METHYL 24 ETHYLCHOLESTA 7,25 DIEN 3 BETA YL ACETATE; 7 O METHYLLUTEOLIN 6 C BETA GLUCOSIDE; ASTRAGALIN; CHINESE DRUG; CHOLESTERYL BENZOATE; EPICATECHIN; GLYCITEIN; HYPERIN; ISORHAMNETIN 3 O RUTINOSIDE; KAEMPFEROL; MUTATOXANTHIN; PHOSPHOLIPID; PHYSCION 8 O BETA DEXTRO GENTIOBIOSIDE; PLANT MEDICINAL PRODUCT; QUERCETIN; RHODIOSIN; RUTOSIDE; UNCLASSIFIED DRUG; VITAMIN K GROUP; XINNAOXIN PILL;

ANGIOGENESIS; ARTICLE; BLOOD BRAIN BARRIER; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHINESE MEDICINE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG TARGETING; HEART MUSCLE CONTRACTILITY; HOLISTIC CARE; HUMAN; INFLAMMATION; INTESTINE ABSORPTION; PRIORITY JOURNAL;

EID: 84935887351     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2015/980190     Document Type: Article

References (70)

1. S. Ventegodt, N. J. Andersen, and J. Merrick, "Holistic medicine: scientific challenges, " TheScientificWorldJOURNAL, vol. 3, pp. 1108-1116, 2003.
2. Y. Wang and A. Xu, "Zheng: a systems biology approach to diagnosis and treatments, " Science, vol. 346, no. 6216, supplement, pp. S13-S15, 2014.
3. W. M. Gesler, "Therapeutic land scapes: medical issues in light of the new cultural geography, " Social Science & Medicine, vol. 34, no. 7, pp. 735-746, 1992.
4. C. Auffray, Z. Chen, and L. Hood, "Systemsmedicine: the future of medical genomics and healthcare, " Genome Medicine, vol. 1, no. 1, article 2, 2009.
5. J. Craig, "Complex diseases: research and applications, " Nature Education, vol. 1, no. 1, p. 184, 2008.
6. C. Ronco, M. Haapio, A. A. House, N. Anavekar, and R. Bellomo, "Cardiorenal syndrome, " Journal of the American College of Cardiology, vol. 52, no. 19, pp. 1527-1539, 2008.
7. X. Li, X. Xu, J. Wang, et al., "A system-level investigation into the mechanisms of chinese traditional medicine: compound danshen formula for cardiovascular disease treatment, " PLoS ONE, vol. 7, no. 9, Article ID e43918, 2012.
8. P. Jiang, R. Liu, S. Dou, et al., "Analysis of the constituents in rat plasma after oral administration of Shexiang Baoxin pill by HPLC-ESI-MS/MS, " Biomedical Chromatography, vol. 23, no. 12, pp. 1333-1343, 2009.
9. W. Tao, X. Xu, X. Wang, et al., "Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease, " Journal of Ethnopharmacology, vol. 145, no. 1, pp. 1-10, 2013.
10. X. Wang, X. Xu, Y. Li, et al., "Systems pharmacology uncovers Janus functions of botanical drugs: activation of host defense system and inhibition of influenza virus replication, " Integrative Biology, vol. 5, no. 2, pp. 351-371, 2013.
11. H. Liu, J. Wang, W. Zhou, Y. Wang, and L. Yang, "Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice, " Journal of Ethnopharmacology, vol. 146, no. 3, pp. 773-793, 2013.
12. D. K. W. Mok and F.-T. Chau, "Chemical information ofChinese medicines: a challenge to chemist, " Chemometrics and Intelligent Laboratory Systems, vol. 82, no. 1-2, pp. 210-217, 2006.
13. T. W. Lau, F. F. Y. Lam, K. M. Lau, et al., "Pharmacological investigation on the wound healing effects of Radix Rehmanniae in an animal model of diabetic foot ulcer, " Journal of Ethnopharmacology, vol. 123, no. 1, pp. 155-162, 2009.
14. H. Yu, J. Chen, X. Xu, et al., "A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data, " PLoS ONE, vol. 7, no. 5, Article ID e37608, 2012.
15. P. A. Heidenreich, J. G. Trogdon, O. A. Khavjou, et al., "Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association, " Circulation, vol. 123, no. 8, pp. 933-944, 2011.
16. M. V. S. Varma, R. S. Obach, C. Rotter, et al., "Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination, " Journal of Medicinal Chemistry, vol. 53, no. 3, pp. 1098-1108, 2010.
17. X. Xu, W. Zhang, C. Huang, et al., "Anovel chemometric method for the prediction of human oral bioavailability, " International Journal ofMolecular Sciences, vol. 13, no. 6, pp. 6964-6982, 2012.
18. P. Geladi and B. R. Kowalski, "Partial least-squares regression: a tutorial, " Analytica Chimica Acta, vol. 185, pp. 1-17, 1986.
19. T. Hou and X. Xu, "ADME evaluation in drug discovery, " Molecular Modeling Annual, vol. 8, no. 12, pp. 337-349, 2002.
20. A. Guerra, N. E. Campillo, and J. A. Paez, "Neural computational prediction of oral drug absorption based on CODES 2D descriptors, " European Journal of Medicinal Chemistry, vol. 45, no. 3, pp. 930-940, 2010.
21. T. L. Moda and A. D. Andricopulo, "Consensus hologram QSAR modeling for the prediction of human intestinal absorption, " Bioorganic & Medicinal Chemistry Letters, vol. 22, no. 8, pp. 2889-2893, 2012.
22. Y. Yao, X. Zhang, Z. Wang, et al., "Deciphering the combination principles of Traditional Chinese Medicine from a systems pharmacology perspective based on Ma-huang Decoction, " Journal of Ethnopharmacology, vol. 150, no. 2, pp. 619-638, 2013.
23. Y. Yamanishi, M. Kotera, M. Kanehisa, and S. Goto, "Drugtarget interaction prediction fromchemical, genomic and pharmacological data in an integrated framework, " Bioinformatics, vol. 26, no. 12, Article ID btq176, pp. i246-i254, 2010.
24. D. S. Wishart, C. Knox, A. C. Guo, et al., "DrugBank: a comprehensive resource for in silico drug discovery and exploration, " Nucleic Acids Research, vol. 34, pp. D668-D672, 2006.
25. L. Li, Y. Li, Y. Wang, and S. Zhang, "Prediction of BBB permeation based on molecular indices, " Chinese Journal ofMedicinal Chemistry, vol. 17, no. 4, pp. 221-228, 2007.
26. R. B. Altman, "PharmGKB: a logical home for knowledge relating genotype to drug response phenotype, "NatureGenetics, vol. 39, no. 4, article 426, 2007.
27. X. Chen, Z. L. Ji, and Y. Z. Chen, "TTD: therapeutic target database, " Nucleic Acids Research, vol. 30, no. 1, pp. 412-415, 2002.
28. A. P. Davis, C. G. Murphy, R. Johnson, et al., "The comparative toxicogenomics database: update 2013, " Nucleic Acids Research, vol. 41, no. 1, pp. D1104-D1114, 2013.
29. M. E. Smoot, K. Ono, J. Ruscheinski, P.-L. Wang, and T. Ideker, "Cytoscape 2. 8: new features for data integration and network visualization, " Bioinformatics, vol. 27, no. 3, Article ID btq675, pp. 431-432, 2011.
30. C. Huang, C. Zheng, Y. Li, Y. Wang, A. Lu, and L. Yang, "Systems pharmacology in drug discovery and therapeutic insight for herbal medicines, " Briefings in Bioinformatics, vol. 15, no. 5, pp. 710-733, 2014.
31. G. Bindea, B. Mlecnik, H. Hackl, et al., "ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks, " Bioinformatics, vol. 25, no. 8, pp. 1091-1093, 2009.
32. P. Knekt, J. Kumpulainen, R. Jarvinen, et al., "Flavonoid intake and risk of chronic diseases, " The American Journal of Clinical Nutrition, vol. 76, no. 3, pp. 560-568, 2002.
33. S. Egert, A. Bosy-Westphal, J. Seiberl, et al., "Quercetin reduces systolic blood pressure and plasma oxidised lowdensity lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study, " British Journal of Nutrition, vol. 102, no. 7, pp. 1065-1074, 2009.
34. H.-J. Kwon, Y. B. Ryu, H. J. Jeong, et al., "Rhodiosin, an antioxidant flavonol glycoside from Rhodiola rosea, " Journal of the Korean Society for Applied Biological Chemistry, vol. 52, no. 5, pp. 486-492, 2009.
35. B. J. Willcox, J. D. Curb, and B. L. Rodriguez, "Antioxidants in cardiovascular health and disease: key lessons from epidemiologic studies, " The American Journal of Cardiology, vol. 101, no. 10, pp. S75-S86, 2008.
36. C. R. Cederroth and S. Nef, "Soy, phytoestrogens and metabolism: a review, " Molecular and Cellular Endocrinology, vol. 304, no. 1-2, pp. 30-42, 2009.
37. N. I. Krinsky, "Carotenoids as antioxidants, " Nutrition, vol. 17, no. 10, pp. 815-817, 2001.
38. Y. Yamamoto and E. Oue, "Antihypertensive effect of quercetin in rats fedwith a high-fat high-sucrose diet, " Bioscience, Biotechnology and Biochemistry, vol. 70, no. 4, pp. 933-939, 2006.
39. I. Mackraj, T. Govender, and S. Ramesar, "The antihypertensive effects of quercetin in a salt-sensitive model of hypertension, " Journal of Cardiovascular Pharmacology, vol. 51, no. 3, pp. 239-245, 2008.
40. M.-X. Jiang, X.-F. Ruan, and Y. Xu, "Effects of Kanlijian on exercise tolerance, quality of life, and frequency of heart failure aggravation in patients with chronic heart failure, " Chinese Journal of Integrative Medicine, vol. 12, no. 2, pp. 94-100, 2006.
41. D. L. Tribble, "Further evidence of the cardiovascular benefits of diets enriched in carotenoids, "The American Journal of Clinical Nutrition, vol. 68, no. 3, pp. 521-522, 1998.
42. H. K. Kim, H. R. Park, J. S. Lee, T. S. Chung, H. Y. Chung, and J. Chung, "Down-regulation of iNOS and TNF-κ expression by kaempferol via NF-κB inactivation in aged rat gingival tissues, " Biogerontology, vol. 8, no. 4, pp. 399-408, 2007.
43. G. L. Firestone and S. N. Sundar, "Anticancer activities of artemisinin and its bioactive derivatives, " Expert Reviews in Molecular Medicine, vol. 11, article e32, 2009.
44. J. B. Toledo, S. E. Arnold, K. Raible, et al., "Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimers Coordinating Centre, " Brain, vol. 136, no. 9, pp. 2697-2706, 2013.
45. A. R. Inacio, K. Ruscher, L. Leng, R. Bucala, and T. Deierborg, "Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke, " Journal of Cerebral Blood Flow & Metabolism, vol. 31, no. 4, pp. 1093-1106, 2011.
46. A. Bierhaus, T. Fleming, S. Stoyanov, et al., "Methylglyoxal modification ofNa v 1. 8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy, " Nature Medicine, vol. 18, no. 6, pp. 926-933, 2012.
47. M. J. Cipolla, Q. Huang, and J. G. Sweet, "Inhibition of protein kinase Cβ reverses increased blood-brain barrier permeability during hyperglycemic stroke and prevents edema formation in vivo, " Stroke, vol. 42, no. 11, pp. 3252-3257, 2011.
48. M. Mendioroz, I. Fernand ez-Cadenas, A. Rosell, et al., "Osteopontin predicts long-termfunctional outcome among ischemic stroke patients, " Journal of Neurology, vol. 258, no. 3, pp. 486-493, 2011.
49. A. Pollak, A. Rokach, A. Blumenfeld, L. J. Rosen, L. Resnik, and R. D. Pollak, "Association of oestrogen receptor alpha gene polymorphism with the angiographic extent of coronary artery disease, " European Heart Journal, vol. 25, no. 3, pp. 240-245, 2004.
50. T. A. Kunnas, P. Laippala, A. Penttila, T. Lehtimaki, and P. J. Karhunen, "Association of polymorphism of human α oestrogen receptor gene with coronary artery disease in men: a necropsy study, " The British Medical Journal, vol. 321, no. 7256, pp. 273-274, 2000.
51. K. M. Fischer, C. T. Cottage, M. H. Konstand in, M. Volkers, M. Khan, and M. A. Sussman, "Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling, " Journal of Molecular and Cellular Cardiology, vol. 51, no. 4, pp. 554-558, 2011.
52. M. van der Paardt, J. B. A. Crusius, M. A. Garcia-Gonzalez, B. A. C. Dijkmans, A. S. Pena, and I. E. van der Horst-Bruinsma, "Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor β1 (TGFB1) gene polymorphisms, " Annals of the Rheumatic Diseases, vol. 64, no. 4, pp. 616-619, 2005.
53. G. Z. Feuerstein, T. Liu, and F. C. Barone, "Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha, " Cerebrovascular and BrainMetabolismReviews, vol. 6, no. 4, pp. 341-360, 1994.
54. J. C. Braz, K. Gregory, A. Pathak, et al., "PKC-α regulates cardiac contractility and propensity toward heart failure, " Nature Medicine, vol. 10, no. 3, pp. 248-254, 2004.
55. S. A. Crone, Y.-Y. Zhao, L. Fan, et al., "ErbB2 is essential in the prevention of dilated cardiomyopathy, " Nature Medicine, vol. 8, no. 5, pp. 459-465, 2002.
56. L. Maier, D. Bers, and J. Brown, "Calmodulin and Ca2+/calmodulin kinases in the heart-physiology and pathophysiology, " Cardiovascular Research, vol. 73, no. 4, pp. 629-630, 2007.
57. S. Gately and W. W. Li, "Multiple roles ofCOX-2 in tumor angiogenesis: a target for antiangiogenic therapy, " Seminars in Oncology, vol. 31, no. 7, pp. 2-11, 2004.
58. T. Murohara and T. Asahara, "Nitric oxide and angiogenesis in cardiovascular disease, " Antioxidants and Redox Signaling, vol. 4, no. 5, pp. 825-831, 2002.
59. A. J. Marrogi, W. D. Travis, J. A. Welsh, et al., "Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma, " Clinical Cancer Research, vol. 6, no. 12, pp. 4739-4744, 2000.
60. R. Aebersold and M. Mann, "Mass spectrometry-based proteomics, " Nature, vol. 422, no. 6928, pp. 198-207, 2003.
61. M. S. Joshi, C. Mineo, P. W. Shaul, and J. A. Bauer, "Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear, " The FASEB Journal, vol. 21, no. 11, pp. 2655-2663, 2007.
62. J.-F. Arnal, A.-T. Dinh-Xuan, M. Pueyo, B. Darblade, and J. Rami, "Endothelium-derived nitric oxide and vascular physiology and pathology, " Cellular and Molecular Life Sciences, vol. 55, no. 8-9, pp. 1078-1087, 1999.
63. C. Monaco, N. Terrand o, and K. S. Midwood, "Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis, " Arthritis Care&Research, vol. 63, no. 4, pp. 500-511, 2011.
64. D. J. H. McCabe, P. Harrison, I. J. Mackie, et al., "Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack, " British Journal of Haematology, vol. 125, no. 6, pp. 777-787, 2004.
65. P. A. Cahill and E. M. Redmond, "Alcohol and cardiovascular disease-modulation of vascular cell function, " Nutrients, vol. 4, no. 4, pp. 297-318, 2012.
66. L. Ferini-Strambi, A. S. Walters, and D. Sica, "The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease, " Journal of Neurology, vol. 261, no. 6, pp. 1051-1068, 2014.
67. J.-C. Reil, F. Custodis, K. Swedberg, et al., "Heart rate reduction in cardiovascular disease and therapy, " Clinical Research in Cardiology, vol. 100, no. 1, pp. 11-19, 2011.
68. C. A. Herzog, R. W. Asinger, A. K. Berger, et al., "Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO), " Kidney International, vol. 80, no. 6, pp. 572-586, 2011.
69. R. M. Freedom, F. S. Rosen, and A. S. Nadas, "Congenital cardiovascular disease and anomalies of the third and fourth pharyngeal pouch, " Circulation, vol. 46, no. 1, pp. 165-172, 1972.
70. L. Hood and M. Flores, "A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory, " New Biotechnology, vol. 29, no. 6, pp. 613-624, 2012.